What is Leerink Partnrs’ Estimate for ACRS FY2029 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the biotechnology company will post earnings per share of ($1.02) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.86) per share.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The company had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $8.31 million.

ACRS has been the subject of several other reports. Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $3.00 to $13.00 in a research report on Monday, November 18th. BTIG Research upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Tuesday, November 19th. Leerink Partners raised Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Jefferies Financial Group raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Finally, HC Wainwright raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $11.00.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS opened at $2.49 on Thursday. The company’s fifty day moving average price is $2.85 and its 200-day moving average price is $2.05. The firm has a market capitalization of $177.86 million, a price-to-earnings ratio of -4.79 and a beta of 0.50. Aclaris Therapeutics has a one year low of $0.95 and a one year high of $5.17.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of hedge funds have recently modified their holdings of the company. Millennium Management LLC grew its stake in shares of Aclaris Therapeutics by 1.9% in the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock worth $3,671,000 after purchasing an additional 63,358 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in Aclaris Therapeutics in the 3rd quarter worth approximately $214,000. BML Capital Management LLC grew its position in shares of Aclaris Therapeutics by 9.7% in the 3rd quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock worth $16,388,000 after buying an additional 1,261,866 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Aclaris Therapeutics by 187.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 216,826 shares during the period. Finally, Stonepine Capital Management LLC raised its holdings in shares of Aclaris Therapeutics by 27.6% during the third quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock valued at $2,828,000 after acquiring an additional 531,427 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Insider Activity at Aclaris Therapeutics

In other news, Director Anand Mehra bought 666,666 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the completion of the purchase, the director now directly owns 710,030 shares in the company, valued at $1,597,567.50. This represents a 1,537.37 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 6.40% of the stock is currently owned by company insiders.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.